. . . . . . . . . . . . . . . . . . . . . . . "TextLocation" . "Results" . "a(CHEBI:glucosamine) -> p(RGD:Irs1,pmod(P,S,612))" . "kin(p(RGD:Map2k1)) -> (a(CHEBI:glucosamine) -> p(RGD:Irs1,pmod(P,S,612)))" . "Approximately 2000 hand curated statements drawn from 57 PubMeds." . "Copyright (c) 2011-2012, Selventa. All Rights Reserved." . "BEL Framework Small Corpus Document" . "Creative Commons Attribution-Non-Commercial-ShareAlike 3.0 Unported License" . . "1.6" . "Exposure of RIN β-cells to glucosamine increased phosphorylation of both IRS-1 Ser307\nand IRS-1 Ser612, which was reversed by treatment with either a cell-permeable\nJNK inhibitor or PD98059, a reversible MAPK kinase (MEK)1 inhibitor, the enzyme\nthat directly activates ERK1/2, respectively (Fig. 10, A and B)" . . "support@belframework.org" . "Selventa" . . . . "2014-07-03T14:29:33.113+02:00"^^ . . .